Switch to:
Also traded in: Austria, Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.90
OTCPK:BAYRY's Cash-to-Debt is ranked lower than
67% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. OTCPK:BAYRY: 0.90 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:BAYRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.25 Max: No Debt
Current: 0.9
0.08
No Debt
Equity-to-Asset 0.51
OTCPK:BAYRY's Equity-to-Asset is ranked lower than
70% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. OTCPK:BAYRY: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:BAYRY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.35 Max: 0.51
Current: 0.51
0.21
0.51
Debt-to-Equity 0.37
OTCPK:BAYRY's Debt-to-Equity is ranked lower than
54% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. OTCPK:BAYRY: 0.37 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:BAYRY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16  Med: 0.67 Max: 1.72
Current: 0.37
0.16
1.72
Debt-to-EBITDA 1.53
OTCPK:BAYRY's Debt-to-EBITDA is ranked higher than
57% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. OTCPK:BAYRY: 1.53 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:BAYRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.08  Med: 1.87 Max: 2.54
Current: 1.53
1.08
2.54
Interest Coverage 7.53
OTCPK:BAYRY's Interest Coverage is ranked lower than
72% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. OTCPK:BAYRY: 7.53 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.86  Med: 5.42 Max: 7.53
Current: 7.53
2.86
7.53
Piotroski F-Score: 7
Altman Z-Score: 2.47
Beneish M-Score: -2.75
WACC vs ROIC
5.44%
11.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 17.60
OTCPK:BAYRY's Operating Margin % is ranked higher than
74% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. OTCPK:BAYRY: 17.60 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:BAYRY' s Operating Margin % Range Over the Past 10 Years
Min: 7.78  Med: 12.94 Max: 17.6
Current: 17.6
7.78
17.6
Net Margin % 18.99
OTCPK:BAYRY's Net Margin % is ranked higher than
83% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. OTCPK:BAYRY: 18.99 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:BAYRY' s Net Margin % Range Over the Past 10 Years
Min: 3.71  Med: 7.35 Max: 20.95
Current: 18.99
3.71
20.95
ROE % 20.18
OTCPK:BAYRY's ROE % is ranked higher than
86% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. OTCPK:BAYRY: 20.18 )
Ranked among companies with meaningful ROE % only.
OTCPK:BAYRY' s ROE % Range Over the Past 10 Years
Min: 6.9  Med: 14.63 Max: 21.85
Current: 20.18
6.9
21.85
ROA % 9.13
OTCPK:BAYRY's ROA % is ranked higher than
76% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. OTCPK:BAYRY: 9.13 )
Ranked among companies with meaningful ROA % only.
OTCPK:BAYRY' s ROA % Range Over the Past 10 Years
Min: 2.54  Med: 5.19 Max: 9.33
Current: 9.13
2.54
9.33
ROC (Joel Greenblatt) % 34.88
OTCPK:BAYRY's ROC (Joel Greenblatt) % is ranked higher than
77% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. OTCPK:BAYRY: 34.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:BAYRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 20.15  Med: 27.7 Max: 34.88
Current: 34.88
20.15
34.88
3-Year Revenue Growth Rate -7.00
OTCPK:BAYRY's 3-Year Revenue Growth Rate is ranked lower than
82% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. OTCPK:BAYRY: -7.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:BAYRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.6  Med: 2.5 Max: 11.1
Current: -7
-10.6
11.1
3-Year EBITDA Growth Rate -2.70
OTCPK:BAYRY's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. OTCPK:BAYRY: -2.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:BAYRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -23.2  Med: 4.2 Max: 15.4
Current: -2.7
-23.2
15.4
3-Year EPS without NRI Growth Rate -2.50
OTCPK:BAYRY's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. OTCPK:BAYRY: -2.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:BAYRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.8 Max: 39.3
Current: -2.5
0
39.3
» OTCPK:BAYRY's 30-Y Financials

Financials (Next Earnings Date: 2018-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

BAYRY Guru Trades in Q2 2017

Ken Fisher 4,934,267 sh (+0.85%)
» More
Q3 2017

BAYRY Guru Trades in Q3 2017

Barrow, Hanley, Mewhinney & Strauss 1,261,356 sh (New)
Ken Fisher 20,620,341 sh (+4.48%)
» More
Q4 2017

BAYRY Guru Trades in Q4 2017

Ken Fisher 20,838,342 sh (+1.06%)
Barrow, Hanley, Mewhinney & Strauss Sold Out
» More
Q1 2018

BAYRY Guru Trades in Q1 2018

Ken Fisher 21,668,714 sh (+3.98%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Add 3.98%0.03%$27.75 - $33.71 $ 29.02-5%21,668,714
Ken Fisher 2017-12-31 Add 1.06%0.01%$30.78 - $35.29 $ 29.02-11%20,838,342
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Sold Out 0.06%$30.78 - $35.29 $ 29.02-11%0
Ken Fisher 2017-09-30 Add 4.48%0.04%$30.64 - $33.38 $ 29.02-10%20,620,341
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 New Buy0.06%$30.64 - $33.38 $ 29.02-10%1,261,356
Ken Fisher 2017-06-30 Add 0.85%0.01%$27.82 - $34.75 $ 29.02-8%19,737,068
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:GSK, XPAR:SAN, NYSE:LLY, LSE:AZN, NYSE:BMY, NYSE:ABBV, NYSE:MRK, TSE:4503, TSE:4519, TSE:4578, XSWX:NOVN, TSE:4568, HKSE:01093, XSWX:ROG, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC » details
Traded in other countries:BAYN.Austria, BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Headquarter Location:Germany
Bayer AG is active in the German healthcare sector. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and animal health products.

Bayer is a German healthcare and chemical conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and animal health products. The company has a crop science business that includes pesticides, herbicides, and fungicides, as well as a material science segment that produces plastics, including polyurethane and polycarbonate. The remaining ownership of the material science group is likely to be sold in the near term.

Top Ranked Articles about Bayer AG

June 15 Forum Update: 'Mega Mergers' Edition A deeper understanding of mergers and acquisitions
During May and June, GuruFocus Forum users discussed mergers and acquisitions in light of the landmark federal court ruling that enabled AT&T Inc. (NYSE:T) to complete its merger with Time Warner Inc. (NYSE:TWX). Read more...
Bayer Closes Merger With Buffett’s Monsanto Combined company expects to improve productivity and sustainability of agricultural companies
Bayer AG (XTER:BAYN)(BAYRY) announced on Thursday that it closed its merger with Monsanto Co. (NYSE:MON), a company Warren Buffett (Trades, Portfolio) invested in 7.26 million shares during the first quarter. Read more...
Bayer Plans to Close Monsanto Takeover on Thursday The German global pharmaceutical and life sciences company counts on receiving all the remaining approvals from the regulator
The stock in Monsanto Co. (NYSE:MON) closed slightly at $127.83 a share, up 0.24%, following Bayer AG’s (OTCPK:BAYRY) announcement about its plans to complete the $63 billion merger before Friday. Read more...
David Herro Starts 4 Positions in 4th Quarter Guru’s largest new stake is in Bayer
David Herro (Trades, Portfolio), portfolio manager of the Oakmark International Fund, disclosed he established four new positions when he released his first-quarter portfolio last week. Read more...
Justice Department Approves Bayer’s Acquisition of Monsanto The company agreed to sell more assets to competitor
After months of back-and-forth negotiations between Bayer AG (XTER:BAYN) (BAYRY) and regulators, the Wall Street Journal reported on Monday the company made a deal with the U.S. Justice Department for antitrust approval of its $62.5 billion takeover of Monsanto Co. (NYSE:MON). Read more...
4 Stocks Move Monday Monsanto, GM, Therapix Biosciences and Merck rise
Monsanto Co. (NYSE:MON) shares surged on a Wall Street Journal report that the U.S. Justice Department approved the pending $66 billion acquisition by Bayer (BAYRY) after the company agreed to sell additional assets to secure government antitrust approval. Read more...
Judge's Order Sets 1,200 Xarelto Product Liability Lawsuits for Separate Jury Trials
Report: More than 15,000 Adverse Events Linked to Xarelto in 2016

Ratios

vs
industry
vs
history
PE Ratio 11.23
BAYRY's PE Ratio is ranked higher than
89% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. BAYRY: 11.23 )
Ranked among companies with meaningful PE Ratio only.
BAYRY' s PE Ratio Range Over the Past 10 Years
Min: 8.62  Med: 22.31 Max: 36.41
Current: 11.23
8.62
36.41
Forward PE Ratio 14.66
BAYRY's Forward PE Ratio is ranked higher than
72% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. BAYRY: 14.66 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.64
BAYRY's PE Ratio without NRI is ranked higher than
60% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. BAYRY: 21.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAYRY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.53  Med: 23.49 Max: 36.98
Current: 21.64
14.53
36.98
Price-to-Owner-Earnings 8.70
BAYRY's Price-to-Owner-Earnings is ranked higher than
91% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.72 vs. BAYRY: 8.70 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAYRY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.23  Med: 14.05 Max: 27.55
Current: 8.7
7.23
27.55
PB Ratio 2.07
BAYRY's PB Ratio is ranked higher than
63% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. BAYRY: 2.07 )
Ranked among companies with meaningful PB Ratio only.
BAYRY' s PB Ratio Range Over the Past 10 Years
Min: 1.52  Med: 2.62 Max: 5.47
Current: 2.07
1.52
5.47
PS Ratio 2.13
BAYRY's PS Ratio is ranked higher than
64% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. BAYRY: 2.13 )
Ranked among companies with meaningful PS Ratio only.
BAYRY' s PS Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.5 Max: 2.77
Current: 2.13
0.86
2.77
Price-to-Free-Cash-Flow 14.28
BAYRY's Price-to-Free-Cash-Flow is ranked higher than
74% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. BAYRY: 14.28 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAYRY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.15  Med: 16.45 Max: 244.92
Current: 14.28
7.15
244.92
Price-to-Operating-Cash-Flow 10.12
BAYRY's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. BAYRY: 10.12 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAYRY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.42  Med: 10.31 Max: 19.1
Current: 10.12
5.42
19.1
EV-to-EBIT 12.54
BAYRY's EV-to-EBIT is ranked higher than
73% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. BAYRY: 12.54 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 16 Max: 26.6
Current: 12.54
7.6
26.6
EV-to-EBITDA 8.77
BAYRY's EV-to-EBITDA is ranked higher than
81% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. BAYRY: 8.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 9.3 Max: 16.8
Current: 8.77
4.3
16.8
EV-to-Revenue 2.13
BAYRY's EV-to-Revenue is ranked higher than
69% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. BAYRY: 2.13 )
Ranked among companies with meaningful EV-to-Revenue only.
BAYRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 1.9 Max: 3.3
Current: 2.13
0.8
3.3
PEG Ratio 12.83
BAYRY's PEG Ratio is ranked lower than
78% of the 318 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. BAYRY: 12.83 )
Ranked among companies with meaningful PEG Ratio only.
BAYRY' s PEG Ratio Range Over the Past 10 Years
Min: 1.13  Med: 3.29 Max: 16.82
Current: 12.83
1.13
16.82
Shiller PE Ratio 22.04
BAYRY's Shiller PE Ratio is ranked higher than
70% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. BAYRY: 22.04 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAYRY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.27  Med: 28.93 Max: 44.68
Current: 22.04
18.27
44.68
Current Ratio 2.53
BAYRY's Current Ratio is ranked lower than
56% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. BAYRY: 2.53 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.56 Max: 2.53
Current: 2.53
1
2.53
Quick Ratio 2.04
BAYRY's Quick Ratio is ranked lower than
56% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. BAYRY: 2.04 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.04 Max: 2.04
Current: 2.04
0.64
2.04
Days Inventory 197.07
BAYRY's Days Inventory is ranked lower than
76% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. BAYRY: 197.07 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.63  Med: 143.05 Max: 263.26
Current: 197.07
126.63
263.26
Days Sales Outstanding 91.35
BAYRY's Days Sales Outstanding is ranked higher than
50% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. BAYRY: 91.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.01  Med: 71.04 Max: 114.58
Current: 91.35
66.01
114.58
Days Payable 105.51
BAYRY's Days Payable is ranked higher than
74% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. BAYRY: 105.51 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 54.65  Med: 83.03 Max: 199.02
Current: 105.51
54.65
199.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.82
BAYRY's Dividend Yield % is ranked higher than
74% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. BAYRY: 2.82 )
Ranked among companies with meaningful Dividend Yield % only.
BAYRY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.44  Med: 2.46 Max: 3.93
Current: 2.82
1.44
3.93
Dividend Payout Ratio 0.68
BAYRY's Dividend Payout Ratio is ranked lower than
82% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. BAYRY: 0.68 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAYRY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.55 Max: 0.88
Current: 0.68
0.46
0.88
3-Year Dividend Growth Rate 8.70
BAYRY's 3-Year Dividend Growth Rate is ranked higher than
55% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. BAYRY: 8.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAYRY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.7 Max: 34.9
Current: 8.7
0
34.9
Forward Dividend Yield % 2.84
BAYRY's Forward Dividend Yield % is ranked higher than
73% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BAYRY: 2.84 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.56
BAYRY's 5-Year Yield-on-Cost % is ranked higher than
82% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. BAYRY: 4.56 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAYRY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.33  Med: 3.98 Max: 6.36
Current: 4.56
2.33
6.36

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.27
BAYRY's Price-to-Tangible-Book is ranked lower than
76% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. BAYRY: 6.27 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BAYRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.6  Med: 3.31 Max: 1178.29
Current: 6.27
0.6
1178.29
Price-to-Intrinsic-Value-Projected-FCF 1.12
BAYRY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. BAYRY: 1.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAYRY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.5 Max: 4.03
Current: 1.12
0.78
4.03
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.54
BAYRY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
53% of the 87 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.52 vs. BAYRY: 1.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BAYRY' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.12  Med: 1.64 Max: 3.31
Current: 1.54
1.12
3.31
Price-to-Median-PS-Value 1.42
BAYRY's Price-to-Median-PS-Value is ranked lower than
59% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. BAYRY: 1.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAYRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.83 Max: 1.77
Current: 1.42
0.21
1.77
Price-to-Graham-Number 2.46
BAYRY's Price-to-Graham-Number is ranked lower than
69% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. BAYRY: 2.46 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BAYRY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.46  Med: 2.45 Max: 34.76
Current: 2.46
0.46
34.76
Earnings Yield (Greenblatt) % 7.99
BAYRY's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. BAYRY: 7.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAYRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.8  Med: 6.2 Max: 13.1
Current: 7.99
3.8
13.1
Forward Rate of Return (Yacktman) % 9.35
BAYRY's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. BAYRY: 9.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAYRY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.2  Med: 11.4 Max: 25.6
Current: 9.35
-0.2
25.6

More Statistics

Revenue (TTM) (Mil) $44,705.31
EPS (TTM) $ 2.46
Beta1.22
Volatility17.77%
52-Week Range $27.60 - 35.41
Shares Outstanding (Mil)3,487.26 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 42,851 46,471 43,431
EBIT (Mil $) 8,072 9,491 9,123
EBITDA (Mil $) 10,732 12,321 10,997
EPS ($) 1.98 1.57 1.80
EPS without NRI ($) 1.98 1.57 1.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.76%
Dividends per Share ($) 0.84 0.88 0.89

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}